Navegar por autor "García Campelo, María del Rosario"

Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study

2015- García Campelo, María del Rosario; Vázquez Estévez, Sergio

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)

2019- Provencio, Mariano; Carcereny, Enric; Rodriguez-Abreu, Delvys; Lopez-Castro, Rafael; Guirado, Maria; [et al.]

Lung cancer symptoms at diagnosis: results of a nationwide registry study

2020- Ruano Raviña, Alberto; Provencio, Mariano; Calvo de Juan, Virginia; Carcereny, Enric; Moran, Teresa; [et al.]

Malignant Pleural Mesothelioma: Observational and Retrospective Analysis of Spanish Database (BEMME). The Spanish Lung Cancer Group (SLCG)

2015- García Campelo, María del Rosario; Martinez Lago, Nieves Purificacion

Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel

2015- García Campelo, María del Rosario

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors

2011- Valladares Ayerbes, Manuel; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; Aparicio Gallego, Guadalupe; [et al.]

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

2014- García Campelo, María del Rosario

New insights into molecular mechanisms of sunitinib-associated side effects

2011- Valladares Ayerbes, Manuel; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Figueroa Conde-Valvís, Angélica; Aparicio Gallego, Guadalupe; [et al.]

Non-small cell lung cancer in women: Description of early stages from the Spanish World07 database

2013- García Campelo, María del Rosario

Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG)

2015- García Campelo, María del Rosario

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

2011- García Campelo, María del Rosario

Role of erlotinib in treatment of advanced non-small cell lung cancer

2013- Fernández Nuñez, Natalia; García Campelo, María del Rosario; Quindós Varela, María; Molina Díaz, Aurea

The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer

2020- Akhoundova, D; Mosquera Martínez, Joaquín; Musmann, L E; Britschgi, C; Rütsche, C; [et al.]

Safety and efficacy of vinflunine in long-time therapy of metastatic bladder cancer

2013- Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; Figueroa Conde-Valvís, Angélica; García Campelo, María del Rosario; [et al.]

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

2019- M., Majem; O., Juan; A., Insa; N., Reguart; J.M., Trigo; [et al.]

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

2013- García Campelo, María del Rosario

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

2015- García Campelo, María del Rosario

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

2022- Martínez-García, M.; Servitja Tormo, S.; Vilariño Quintela, N.; Arance Fernández, A.; Berrocal Jaime, A.; [et al.]

Sorafenib in advanced non-small-cell cancer: a retrospective analysis of patients in progression after two or more lines of therapy

2012- Antón Aparicio, Luis Miguel; García Campelo, María del Rosario

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

2014- García Campelo, María del Rosario

Repositorio digital RUNA

Navegar por autor "García Campelo, María del Rosario"

Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study ﻿

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) ﻿

Lung cancer symptoms at diagnosis: results of a nationwide registry study ﻿

Malignant Pleural Mesothelioma: Observational and Retrospective Analysis of Spanish Database (BEMME). The Spanish Lung Cancer Group (SLCG) ﻿

Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel ﻿

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors ﻿

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor ﻿

New insights into molecular mechanisms of sunitinib-associated side effects ﻿

Non-small cell lung cancer in women: Description of early stages from the Spanish World07 database ﻿

Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG) ﻿

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations ﻿

Role of erlotinib in treatment of advanced non-small cell lung cancer ﻿

The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer ﻿

Safety and efficacy of vinflunine in long-time therapy of metastatic bladder cancer ﻿

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) ﻿

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013 ﻿

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 ﻿

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021) ﻿

Sorafenib in advanced non-small-cell cancer: a retrospective analysis of patients in progression after two or more lines of therapy ﻿

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial ﻿

Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)

Lung cancer symptoms at diagnosis: results of a nationwide registry study

Malignant Pleural Mesothelioma: Observational and Retrospective Analysis of Spanish Database (BEMME). The Spanish Lung Cancer Group (SLCG)

Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

New insights into molecular mechanisms of sunitinib-associated side effects

Non-small cell lung cancer in women: Description of early stages from the Spanish World07 database

Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG)

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

Role of erlotinib in treatment of advanced non-small cell lung cancer

The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer

Safety and efficacy of vinflunine in long-time therapy of metastatic bladder cancer

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

Sorafenib in advanced non-small-cell cancer: a retrospective analysis of patients in progression after two or more lines of therapy

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial